Latest News

Page 5 of 25« First...34567...1020...Last »

February 3, 2016

Accessible Driving Is On The Horizon

Posted in: Latest News, Research and Developments

by Dan Roberts A couple of changes are on the horizon which may allow visually impaired people to regain or maintain the pleasure of piloting their own private vehicles whenever and wherever they choose. The most immediate change could come from relaxation of the minimum visual acuity requirements, made possible in part by the development of bioptic
read more »

February 3, 2016

Bausch + Lomb Partners with Prevent Blindness® to Urge Americans to Fight for Their Sight 

Posted in: Latest News

February is Age-related Macular Degeneration Awareness (AMD) Month From Valentine’s Day to American Heart Health Month, February is traditionally the most heart-driven month of the year. This February, Bausch + Lomb is partnering with Prevent Blindness®, the nation’s oldest volunteer eye health and safety organization, dedicated to fighting blindness and saving sight, to encourage the
read more »

January 27, 2016

New Drug Under Study for Dry MD

Posted in: Latest News, Research and Developments

Ophthotech Corporation has announced that the first patient has been dosed in a Phase 2/3 clinical study of Zimura® (avacincaptad pegol sodium) for treatment of advanced dry macular degeneration (MD).  Zimura® is an inhibitor of complement factor C5, a central component of the complement cascade believed to be involved in the development of AMD. The Company has also recently
read more »

January 25, 2016

Let’s Be Clear About Blue Light

Posted in: Latest News, Research and Developments

Editorial by Dan Roberts The media is becoming saturated with warnings about the so-called “blue light hazard”. Let’s pull it back a bit by being more specific about who should be most concerned. In 2006, I published a paper titled Artificial Lighting and the Blue Light Hazard. The purpose of the paper was to warn of
read more »

January 13, 2016

New Study Underway for Treatment of Dry Macular Degeneration

Posted in: Latest News, Research and Developments

Subjects are being sought for trials to test the new Nova Oculus™ device as the only scientifically supported treatment for dry macular degeneration. Presently, no scientifically proven treatment option is available for those with dry macular degeneration (dMD). Ongoing research, however, is showing that a new device using biocurrent technology (very low micro-current electrical stimulation)
read more »

December 23, 2015

Glaucoma Awareness Can Help Save Your Vision

Posted in: Eye Conditions, Latest News

Important Information from the National Eye Institute Glaucoma is a major cause of vision loss in the U.S. While it currently affects about 3 million Americans, estimates show 6.3 million could have glaucoma by 2050. With Glaucoma Awareness Month in January, it’s a good time to think about scheduling a comprehensive dilated eye exam, especially
read more »

December 11, 2015

Triple Therapy with Zeaxanthin Lessens Burden of Treatment for Wet AMD

Posted in: Health and Nutrition, Latest News, Research and Developments

As far back as 2007, triple therapy for wet (neovascular) age-related macular degeneration (AMD) was shown to be superior to mono therapy (intraocular injection of a single anti-VEGF drug).* And now, a study described in a recent online publication of the peer-reviewed monthly, International Journal of Retina and Vitreous, found that triple therapy supplemented with
read more »

December 10, 2015

Delayed Dark Adaptation Predicts Onset of Dry AMD

Posted in: Latest News, Research and Developments

A recent study* at the University of Alabama has found that measurement of the time it takes older adults’ eyes to adapt to the dark can predict onset of dry age-related macular degeneration (dAMD). Using a computerized dark adaptometer, 325 persons with healthy eyes were each subjected to a flash of light in one eye,
read more »

November 16, 2015

X-82 Oral Medication May Reduce Number of Intravitreal Injections for Wet AMD

Posted in: Latest News, Research and Developments

No cure yet exists for wet AMD, but three FDA-approved therapies are slowing the progress of wet AMD and reducing the amount of vision loss. These treatments are ranibizumab (Lucentis), aflibercept (Eylea), and off-label bevacizumab (Avastin). These medications are highly successful, but they must be injected directly into the eye, and the treatment often needs
read more »

November 16, 2015

Iluvien Similar to Anti-VEGF Drugs as Treatment for Diabetic Retinopathy

Posted in: Latest News, Research and Developments, Therapies, Treatments, and Procedures

On February 16, Charles C. Wykoff, MD, PhD, announced to the American Academy of Ophthalmology annual meeting that Iluviuan (fluocinolone acetonide) treatment, after 1.3 injections over 3 years in the FAME trials, “significantly reduced progression to prolific diabetic retinopathy from 31% to 17%, a similar reduction as observed with monthly anti-VEGF treatments.” Iluvian (Alimera Sciences)
read more »

Page 5 of 25« First...34567...1020...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann